We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
-8.25%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$3.75B
AUM Growth
-$833M
Cap. Flow
-$27.3M
Cap. Flow %
-0.73%
Top 10 Hldgs %
47.18%
Holding
110
New
14
Increased
9
Reduced
11
Closed
22

Top Buys

Rank Stock Value
1
VERU icon
Veru
VERU
+$91.7M
2
PEPG icon
PepGen
PEPG
+$90.7M
3
NSTG
NanoString Technologies, Inc.
NSTG
+$66.8M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$36.2M
5
NKTX icon
Nkarta
NKTX
+$28.9M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$60.4M
2
MGNX icon
MacroGenics
MGNX
+$53.8M
3
NVAX icon
Novavax
NVAX
+$51M
4
CNTA
Centessa Pharmaceuticals
CNTA
+$32.1M
5
CCXI
ChemoCentryx, Inc.
CCXI
+$29M

Sector Composition

Rank Sector Weight
1 Healthcare 98.19%
2 Financials 1.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LENZ
101
LENZ Therapeutics
LENZ
$166M
– –
-385,481
Closed -$13.8M
KLRS
102
Kalaris Therapeutics
KLRS
$83.5M
– –
-62,632
Closed -$9.72M
MORF
103
DELISTED
Morphic Holding, Inc. Common Stock
MORF
– –
-278,874
Closed -$11.2M
HLTH
104
DELISTED
Cue Health Inc. Common Stock
HLTH
– –
-750,000
Closed -$4.84M
CYT
105
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
– –
-3,350,506
Closed -$12.6M
MRTX
106
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-734,343
Closed -$60.4M
KDNY
107
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-1,000,000
Closed -$16.4M
AKUS
108
DELISTED
Akouos Inc
AKUS
– –
-2,281,249
Closed -$10.8M
PHAS
109
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
– –
-2,850,000
Closed -$3.76M
CCXI
110
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-1,155,964
Closed -$29M
1 2 3 4
5

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q2 2022 Portfolio in Review

As of Q2 2022, RA Capital Management held 110 positions worth $3.75B, down 18% from $4.58B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

RA Capital Management's Q2 2022 filing shows 14 new, 9 increased, 11 reduced and 22 closed positions. Its largest new stake was Veru: 790,000 shares worth $89.3M. The largest sale was Mirati Therapeutics, Inc. Common Stock, an estimated $60.4M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials.

  • RA Capital Management's largest Q2 2022 buy was Veru: 790,000 shares worth $89.3M.
  • RA Capital Management added most to Aclaris Therapeutics in Q2 2022, an estimated $36.2M increase.
  • RA Capital Management's biggest Q2 2022 reduction was LianBio American Depositary Shares, cutting an estimated $10.3M.
  • RA Capital Management fully exited Mirati Therapeutics, Inc. Common Stock in Q2 2022, selling an estimated $60.4M.
  • RA Capital Management's ten largest holdings make up 47% of its $3.75B portfolio in Q2 2022.
  • RA Capital Management opened 14 new positions and closed 22 in Q2 2022.
  • RA Capital Management's portfolio value fell 18% quarter-over-quarter to $3.75B.

Based on RA Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.